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Abstract
Background: The most often used mumps vaccine strains Jeryl Lynn (JL), RIT4385, Urabe-AM9,
L-Zagreb and L-3 differ in immunogenicity and reactogenicity. Previous analyses showed that JL,
Urabe-AM9 and L-3 are genetically heterogeneous.
Results: We identified the heterogeneity of L-Zagreb throughout the entire genome. Two major
variants were defined: variant A being identical to the consensus sequence of viral seeds and
vaccine(s) and variant B which differs from variant A in three nucleotide positions. The difference
between viral variants in L-Zagreb strain is insufficient for distinct viral strains to be defined. We
demonstrated that proportion of variants in L-Zagreb viral population depends on cell substrate
used for viral replication in vitro and in vivo.
Conclusion: L-Zagreb strain should be considered as a single strain composed of at least two
variant viral genomes.
Background
Mumps virus (MuV) genome consists of a 15 384 nt long
non-segmented single-stranded negative sense RNA. The
genomic RNA contains seven genes which encode nine
open reading frames: NP (nucleoprotein), P (phospho-
protein, V protein, I protein), M (matrix protein), F
(fusion protein), SH (small hydrophobic protein), HN
(haemagglutinin-neuraminidase) and L (large protein)
[1,2].
Mumps virus causes an acute systemic infection involving
glandular, lymphoid and nervous tissues. Prior to the
introduction of live attenuated virus vaccines, mumps
virus was a leading cause of the virus-induced CNS disease
[1].
Live attenuated mumps vaccines have been used world-
wide since late 1960s [3,4]. Nowadays, the most often
used vaccine strains are Jeryl Lynn (JL), RIT 4385, Urabe-
AM9, L-Zagreb and Leningrad-3 (L-3) [5,6].
Although at the time of their development the knowledge
of molecular content of mumps vaccines was not the
issue, recently it has become obvious that the molecular
consistency of vaccine production is not a trivial matter.
Sauder et al [7] showed that the change in genetic hetero-
geneity at the specific genome sites can have a profound
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effect on neurovirulent phenotype of Urabe-AM9 strain.
The RNA viral population consists of virus particles that
differ from the consensus sequence in one or more nucle-
otides (quasisipecies), the feature that arises because of
the high mutation rate of RNA-dependent RNA polymer-
ase (RdRp) (10-3 to 10-5 errors per nucleotide site and rep-
lication cycle) [8,9]. Given that all mumps vaccines are
quasiespecies populations, an adequate description of the
vaccine virus genome should include not only the consen-
sus sequence, but also the quantitative assessment of the
existing viral variants.
Previous analyses confirmed that mumps vaccine strains
JL, Urabe-AM9 and L-3 are genetically heterogeneous. JL is
composed of a mixture of two distinct viral strains (JL5
and JL2) [10,11] while Urabe-AM9 represents a quasispe-
cies mix [12,13].
L-3 vaccine strain was prepared from five mumps virus
isolates combined into a single strain in 1953 [4]. It was
characterized as heterogenic on the basis of plaque mor-
phology [14] and a sequence autoradiogram with several
ambiguities in P and F genes [15] but precise vaccine com-
position of L-3 was never published.
L-Zagreb vaccine strain was developed by further subculti-
vation of L-3 mumps vaccine strain in primary culture of
chicken embryo fibroblast (CEF) [16]. Genetic stability at
the level of the consensus sequence of the L-Zagreb vac-
cine strain in the course of the production process was
demonstrated [17].
Here, we analyzed the detailed genetic composition of L-
Zagreb vaccine strain. Due to mixture of mumps virus iso-
lates in L-3 production and its heterogeneity we wonder
about the composition of L-Zagreb strain.
By two independent cloning experiments we showed that
L-Zagreb vaccine strain contains only one viral strain.
However, numerous nucleotide positions showed to be
heterogenic and indicating a quasispecies nature of this
strain. We successfully isolated two types of viral clones:
identical to consensus sequence, named as variant A, and
with the nucleotide sequences different from the consen-
sus sequence (quasispecies). The most abundant quasis-
pecies, named variant B, was detected in all analyzed L-
Zagreb samples.
Finally, we demonstrated that the heterogenic composi-
tion of L-Zagreb strain strongly depends on the number of
passages and the type of the cell culture that the virus is
replicating on.
Results and discussion
Heterogenic nucleotide positions in the L-Zagreb vaccine 
strain genome
The strategy for defining heterogenic positions in the L-
Zagreb vaccine strain genome involved cloning of eleven
overlapping PCR fragments into pUC19 plasmid vector
and sequencing of resulting plasmid clones. For each frag-
ment, two independent cloning experiments were per-
formed in order to avoid misinterpretation of artificial
heterogeneity arisen from the error of Pfu DNA polymer-
ase used for fragment amplification [18]. Twenty and ten
clones were analyzed in the first and the second experi-
ment, respectively. Cloned genome fragments were com-
pared to the consensus sequence of the L-Zagreb strain
[GenBank: AY685920] in order to select clones with
changed nucleotides.
As a result, 88 and 49 nucleotides different from the con-
sensus sequence were identified throughout a complete
genome of L-Zagreb strain, in the first and the second
experiment respectively (Fig 1). The distribution of the
heterogenic positions seem to be at random except for the
region between approx. 2000 and 3000 nt which corre-
sponds to almost a complete coding region of P gene
(which spans region 1979–3152 nt) where no heteroge-
neity was found (Fig 1).
By comparing changed nucleotides of the first and the sec-
ond cloning experiment, alterations of six nucleotides
(1059, 1073, 1996, 5261, 11345 and 13054) were identi-
fied in both cloning experiments in one or more clones.
Alterations G1059A was identified in 1/20 and 1/10
sequenced plasmid clones, G1073T in 5/20 and 1/10;
A1996C in 1/20 and 1/10, C5261T in 7/20 and 4/10,
G11345T in 5/20 and 3/10 plasmid clones and alteration
C13054A was identified in 2/20 and 1/10 plasmid clones
(Fig 1).
Other 125 changed nucleotides were found within a sin-
gle clone in one of the experiments (Fig 1). They could
easily be considered as possible heterogeneities in L-
Zagreb strain, although it should not be ruled out that
some of them originated from a low error rate of the
enzymes involved in fragment amplification.
Heterogeneity of isolated viral clones
Based on the above results it may be predicted that there
are different viral variants constituting L-Zagreb strain.
However, solely by defining heterogenic positions in
cloned fragments it was not possible to identify the vari-
ants. Therefore, viral clones of the L-Zagreb strain were
plaque isolated in the Vero cell culture and additionally
subcultivated once in the same cell culture. Twelve viral
clones were identified by sequencing in regions which
included six heterogenic positions identified in cloningVirology Journal 2008, 5:79 http://www.virologyj.com/content/5/1/79
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experiments: 1059, 1073, 1996, 5261, 11345 and 13054.
The analysis of the picked viral clones indicated two viral
variants, herein named variant A and variant B. Variant A
was shown to be identical to the consensus sequence in all
6 positions: 1059G, 1073G, 1996A, 5261C, 11345G, and
13054C. Variant B differed from the consensus sequence
in positions 1073T, 5261T and 11345T.
Seven out of 12 analyzed viral clones represented variant
A and five out of 12 represented variant B.
In the process of determination of the viral variants we
used only 6 positions identified as heterogenic by the
cloning experiments. As that could limit the criteria for
defining the variants, a complete genome of one viral
clone belonging to variant B was sequenced and com-
pared to the consensus sequence. Again, the differences
were only in positions 1073, 5261 and 11345, what con-
firmed our criteria for defining variant B as adequate. Also
it confirmed the presence of Ts at positions 1073, 5261
and 11345 as the genetic marker of variant B versus vari-
ant A.
Three positions (1073, 5261 and 11345) which differen-
tiate variants A and B caused diversity in amino acid com-
position of the N (310 aa, A→S), F (239 aa, T→I) and L
(970 aa, V→L) protein. Although these amino acids are
not part of any known functional domains it is difficult to
predict biological impact of these differences since the
molecular structures of mumps virus proteins are not well
characterized.
Heterogenic positions 1059, 1996 and 13054 were not
detected in any of the twelve analyzed viral clones. Since
Schematic presentation of mumps virus genome with changed nucleotides Figure 1
Schematic presentation of mumps virus genome with changed nucleotides. Black triangles represents changes detected in first 
experiment while gray squares represents changes detected in second experiment. Six nucleotides positions are detected as 
changed in both experiments: a = nt 1059, b = nt 1073, c = nt 1996, d = nt 5261, e = nt 11345, f = nt 13054.Virology Journal 2008, 5:79 http://www.virologyj.com/content/5/1/79
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they were identified in both cloning experiments, they can
not be considered as misinterpretation due to the errone-
ous nucleotide incorporation in the amplification proc-
ess. They should rather be considered as differential
positions of viral variants which coexist with variant A and
B, but at low amount. Although heterogenic positions rep-
resented by low amount seem at random and not relevant
for the virus, the in vivo impact of these minor variants
should not be minimized. Previous study [7] indicated
the existence of multiple genetic markers and a need for
evaluation of a total viral population instead of putting
the relevance of a consensus sequence in foreground.
Since L-Zagreb vaccine strain originated from L-3 vaccine
strain [16], we compared the nucleotide sequences of
both variants to the consensus sequence of L-3 [GenBank:
AY508995] (Table 1). Comparison of the entire genome
of L-3 strain with the variant A and variant B genomes
showed difference in five and eight nucleotides, respec-
tively (Table 1). Since the heterogeneity of L-3 strain is not
completely resolved it is not possible to define when the
heterogenic positions in L-Zagreb strain occurred: were
they newly created by mutational process in the course of
adaptation in primary CEF culture or was it the selection
of preexisting minor quasispecies of L-3 strain which
occurred when Japanese quail embryo fibroblast culture
was replaced by primary CEF.
High level of difference between JL5 and JL2 (414 nt, 87
aa), demonstrated JL vaccine as a mixture of two distinct
viral strain [11]. In contrast to JL, the two most abundant
viral variants in L-Zagreb strain differ in three nucleotide
positions (three aa) what is an insufficient variation for
two distinct viral strains to be defined. L-Zagreb strain
should be considered as a single strain composed of a
number of quasispecies viral genomes. Thus, L-Zagreb
strain is similar to Urabe-AM9 vaccine strain which con-
sists of at least two viral variants with minor genetic
changes [19,12,13].
Screening of heterogeneity in the L-Zagreb seeds and 
vaccine lots
Here, the same sample was used for both cloning experi-
ments and plaque isolation. Due to the high genetic plas-
ticity of RNA viruses one could easily assume that the
identified heterogenic positions reflect only the composi-
tion of that sample and is not the intrinsic feature of L-
Zagreb vaccine strain.
Therefore the heterogeneity of L-Zagreb strain was ana-
lyzed in vaccine seeds (master and working) and two final
vaccine batches. The T in heterogenic position 5261 in the
F gene is located within the SspI restriction site while the
C in the same position eliminates this restriction site. The
existence or the absence of restriction site facilitated the
use of PCR-RFLP assay as an adequate method for distin-
guishing the two variants, A and B. A 321 bp uncleaved
fragment indicated variant A while a 219 bp cleaved frag-
ment indicated variant B.
Heterogenic positions 1073 and 11345 which are also
genetic markers of variant B were unsuitable for RFLP
assay. However, it was proved above that these three posi-
tions represent the marker of variant B.
Both variants were detected in all four viral samples, but
at different proportions (Table 2, Fig 2A). The master seed
consisted of 93.0 ± 1.8% variant A and 7.0 ± 1.8% variant
B. In the working seed the proportion of variant B
increased to 9.7 ± 1.1% and the proportion of variant A
decreased to 90.3 ± 1.1%. The two final vaccine batches
contained even lower proportions of variant A (80.4 ±
2.6% and 79.4 ± 2.9%, respectively) and higher propor-
tions of variant B (19.6 ± 2.6% and 20.6 ± 2.9%, respec-
tively) in comparison to the viral seeds.
Altogether, these data indicate that different L-Zagreb vac-
cine strain samples are heterogenic in the same nucleotide
positions. Although the stability of the L-Zagreb consen-
sus sequence of the master seed and a final vaccine batch
was confirmed [17], it is clear that the quasispecies con-
tent is changing by the passage number.
Influence of different cell culture on heterogeneity of L-
Zagreb
Different production stages of L-Zagreb vaccine analyzed
above originated through increasing number of passages
in primary chicken embryo fibroblasts (CEF). Analysis of
the proportion of variants A and B in the vaccine samples
clearly shows that CEF somewhat favor replication of var-
iant B over variant A (Fig 2A). The influence of selected
cell line on replication efficiency of viral clones and thus
a genetic heterogeneity of the entire viral sample was also
reported previously [20].
Table 1: Nucleotide and amino acid differences between L-3 
vaccine strain and variant A (var A) and variant B (var B) of L-
Zagreb strain.
Gene nt position aa position L3:varA L3:varB
leader 14 a→t
30 a→g
---
---
≠
≠
≠
≠
NP 1059 g→a
1073 g→t
305
310
≠
=
≠
≠
F5 0 3 7  a →g
5261 c→t
NC
239
≠
=
≠
≠
L 11345 g→t
15325 t→a
970
NCR
=
≠
≠
≠
(aa amino acid, NC not changed, NCR non-coding region, ≠ non-
identical, = identical)Virology Journal 2008, 5:79 http://www.virologyj.com/content/5/1/79
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A limited number of serial passages of L-Zagreb vaccine
strain in Vero and SH-SY5Y cell line further confirmed the
influence of the cell culture selection on the genetic com-
position of L-Zagreb strain (Fig 2B and 2C). Cell superna-
tants from each of five passages were analyzed by PCR-
RFLP assay in position 5261. The original sample (p0)
contained 77.7 ± 1.5% of variant A and 22.3 ± 1.5% of
variant B. The first passage decreased the proportion of
variant B in both Vero and SH-SY5Y cells to 12.2 ± 1.5%
and 10.0 ± 3.6%, respectively (Fig 2B and 2C, respec-
tively). Surprisingly, the proportion of variant B was
diminished to an undetectable level already in the follow-
ing passage and remained undetectable for the next three
passages in both cell types (Fig 2B and 2C). This clearly
shows that both Vero and SH-SY5Y cells, in contrast to
CEF, promote the replication of variant A leading to the
loss of variant B, the second most abundant genomic var-
iant in L-Zagreb strain.
However, when propagated as a genetically homogenous
viral clone, variant B was able to replicate in both cell
types up to the same extent as variant A (data not shown)
indicating that variant A either uses up the cell capacity to
produce viral particles faster then variant B or it actively
suppresses the replication of variant B by an unknown
mechanism.
Conclusion
Our data confirm heterogeneous nature of the L-Zagreb
mumps vaccine strain and permanent existence of minor
variant B whose replication is favored by the production
cell culture. Variant B differed from consensus sequence in
only tree nucleotides what give us reason to conclude that
vaccine strain L-Zagreb is composed of only one mumps
viral strain. Also we detected low represented variant
changed in nt positions 1059, 1996 and/or 13054.
Sauder et al. [7] showed that changes in the neurovirulent
phenotype were merely associated with the changes of the
level of genetic heterogeneity. In addition to cell substrate,
serial passaging of mumps virus could reduce or increase
neurovirulent phenotype of the virus.
Due to its heterogenic profile, examined L-Zagreb vaccine
lot could serve as comparator in investigations of genetic
profile of L-Zagreb postvaccinal mumps virus [21] or L-
Zagreb horizontally transmitted mumps virus [22].
Materials and methods
Viral material and cell culture
L-Zagreb master and working seeds were stored at -80°C
until used for RNA extraction. Freeze-dried L-Zagreb vac-
cine lots 1 and 2 were reconstituted in 250 μl of water
prior to RNA extraction or in 500 μl of sterile water prior
to plaque assay. All viral materials were produced at the
Institute of Immunology Inc, Zagreb, Croatia.
Vero cell culture (African green monkey kidney cells) was
obtained from the American Type Culture Collection
(USA) and cultured in minimal essential medium (MEM-
H) (AppliChem, Germany) supplemented with 10% fetal
calf serum (FCS) (Moregate, Australia) and neomycin 50
μl/ml (Gibco-BRL, USA). Human neuroblastoma cell cul-
ture, SH-SY5Y was obtained from European Collection of
Cell Cultures, (UK) and cultured in D-MEM medium sup-
plemented with 10% FCS and neomycin 50 μl/ml.
RT-PCR
Viral RNA was extracted from 250 μl of viral seeds or
reconstituted vaccine as reported by Chomczynski and
Mackey [23].
cDNA synthesis and amplification of the complete
genome segmented in eleven overlapping fragments, were
performed as described in Ivancic et al [17]. Briefly, RNA
was reverse transcribed with random hexamers and MuLV
(Applied Biosystems, USA) for 1 h at 42°C. Amplification
was performed with the whole reverse transcription mix
containing 2.4 U Pfu DNA polymerase (Promega, USA) in
a total volume of 100 μl.
Molecular cloning
Successful amplification of fragments of the expected size
was confirmed by electrophoresis in 1% agarose gels. The
fragments were purified using a Qiaquick kit (Qiagen,
Germany) and cloned into pUC19 vector (New England
Biolabs, USA) using protocol for blunt-end cloning
described in pMOSBlue Blunt Ended Cloning Kit (GE
Healthcare, UK) with modification.
Briefly, plasmid DNA was linearised with SmaI  and
dephosphorylated using alkaline phosphatase (Roche,
Germany). DNA fragments were converted into blunt,
phosphorylated products in a one step reaction using PK
enzyme mix from pMOSBlue Blunt Ended Cloning Kit
Table 2: The proportion of variants A and B in the L-Zagreb 
samples: L-Zagreb master seed, L-Zagreb working seed and L-
Zagreb final vaccine lots 1 and 2.
L-Zagreb sample Variant (%)*
AB
Master seed 93.0 ± 1.8 7.0 ± 1.8
Working seed 90.3 ± 1.1 9.7 ± 1.1
Final vaccine lot 1 80.4 ± 2.6 19.6 ± 2.6
Final vaccine lot 2 79.4 ± 2.9 20.6 ± 2.9
* the arithmetic mean ± SD of four independent PCR-RFLP 
experimentsVirology Journal 2008, 5:79 http://www.virologyj.com/content/5/1/79
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The proportion of variant A and variant B detected in position 5261 in mumps virus genome Figure 2
The proportion of variant A and variant B detected in position 5261 in mumps virus genome. The L-Zagreb samples were 
propagated on (a) CEF, (b) Vero, and (c) SH-SY5Y cell cultures. Data from two experiments are presented.Virology Journal 2008, 5:79 http://www.virologyj.com/content/5/1/79
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(GE Healthcare, UK). Followed by brief heat incubation
the product was ligated overnight at 16°C into dephos-
phorylated blunt ended pUC19.
Escherichia coli strain DH5amcrAB (Life Technologies Ltd,
USA) was transformed with the ligation mix. Transformed
bacteria were picked out using blue-white selection. Plas-
mid DNA was isolated from overnight cultures by alkaline
lysis [24].
DNA sequencing
Segments of mumps virus genome were sequenced either
upon cloning into pUC19 vector or directly as PCR prod-
ucts of isolated viral clones by using M13 FSP
(5'gctggcgaaagggggatgtg3') and M13 RSP
(5'cactttatgcttccggctcg3') primers or mumps virus specific
primers [17]. Sequencing was performed on a 3130
Genetic Analyzer (Applied Biosystems, USA) using the
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, USA) according to the protocol recom-
mended by the manufacturer. Obtained sequences were
analyzed by CloneManager Suite software (Scien-
tific&Educational Software, USA).
Isolation of viral clones
The 8 × 105 Vero cells were grown in six-well plates for 24
h. Virus was diluted in MEM-H with 2% FCS and neomy-
cin. Aspirated cell monolayer was infected with 0.5 ml of
viral suspension. After 1 h at 37°C viral suspension was
aspirated, cells were washed twice with PBS and 3 ml of
overlay I (1 v/v 2 × MEM-H with 10% FBS without phenol
red and 1 v/v 1.4% Noble agar (Sigma, USA)). Plates were
incubated at 37°C in a humidified atmosphere of 5%
CO2. After five days 1 ml of overlay II (0.02% Neutral red
(Sigma, USA) plus overlay I) was added. Plates with solid-
ified overlay II were incubated at 37°C for the next 24 h
in a humidified atmosphere of 5% CO2. Viral clones were
cut out and transferred on Vero cells for one additional
passage in order to prepare viral suspension for the viral
identification by DNA sequencing.
Virus passages in cell cultures
Vero and SH-SY5Y were grown in six-well plates for 24 h.
Cells were infected with monovalent L-Zagreb vaccine at
m.o.i. 0.05 and incubated at 37°C for 1 h. Cells were then
washed twice with PBS. Infected Vero and SH-SY5Y cells
were incubated in MEM-H or D-MEM, respectively, with
2% FCS and neomycin at 37°C in a humidified atmos-
phere of 5% CO2. After 48 h the medium was collected
and used for further passage and viral identification by
DNA sequencing. Each consecutive passage was done with
1/10 of collected culture medium. Five consecutive pas-
sages in both cell lines were performed.
PCR-RFLP assay
PCR products were purified by using QIAquick kit (Qia-
gen, Germany) and cleaved in a reaction mixtures consist-
ing of 0.05 μg of PCR product, 10 U of SspI  (GE
Healthcare, UK) and 1× cleavage buffer in a total volume
of 25 μl. The reaction was carried out overnight at 37°C.
Cleaved PCR product was diluted 1:10 with water, and 1
μl was mixed with 0.5 μl of GS-500 LIZ size standard
(Applied Biosystems, USA) and 9.5 μl of HiDi formamide
(Applied Biosystems, USA). The mixture was denaturated
at 95°C for 2 min followed by cooling on ice. Electro-
phoresis of cleaved PCR products was performed on 3130
Genetic Analyzer (Applied Biosystems, USA) using POP7
polymer (Applied Biosystems, USA). Analyses of PCR
products were done by GeneMapper (Applied Biosystems,
USA) software using peak area data [25].
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